Prognostic value of morphology and hormone receptor status in breast cancer -: a population-based study

被引:34
|
作者
Allemani, C
Sant, M
Berrino, F
Aareleid, T
Chaplain, G
Coebergh, JW
Colonna, M
Contiero, P
Danzon, A
Federico, M
Gafà, L
Grosclaude, P
Hédelin, G
Macè-Lesech, J
Garcia, CM
Paci, E
Raverdy, N
Tretarre, B
Williams, EMI
机构
[1] Ist Nazl Studio & Cura Tumori, Epidemiol Unit, I-20133 Milan, Italy
[2] Inst Clin & Expt Med, Dept Epidemiol & Biostat, EE-11619 Tallinn, Estonia
[3] N Estonian Reg Hosp Fdn Canc Ctr, Estonian Canc Registry, EE-11619 Tallinn, Estonia
[4] Fac Med, Ctr Univ Epidemiol Populat, Cote dOr Breast & Gynaecol Canc Registry, F-21000 Dijon, France
[5] Eindhoven Canc Registry, Comprehens Canc Ctr S, NL-5600 EA Eindhoven, Netherlands
[6] Isere Canc Registry, F-38240 Meylan, France
[7] Ist Nazl Studio & Cura Tumori, Lombardy Canc Registry, I-20133 Milan, Italy
[8] CHU Besancon, Doubs Canc Registry, F-25030 Besancon, France
[9] Policlin, Modena Canc Registry, I-41100 Modena, Italy
[10] Ragusa Canc Registry, I-97100 Ragusa, Italy
[11] Tam Canc Registry Rech Epidemiol & Prevent, F-81001 Albi, France
[12] Fac Med Strasbourg, Bas Rhin Canc Registry, Lab Epidemiol & Sante Publ, F-67085 Strasbourg, France
[13] Ctr Francois Baclesse, Calvados Canc Registry, F-14021 Caen, France
[14] Escuela Andaluza SAlud Publ, Granada Canc Registry, E-18080 Granada, Spain
[15] Ao Careggi CSPO, UO Epidemiol Clin & Descritt, Tuscany Canc Registry, I-50135 Florence, Italy
[16] CHR Nord, Assoc Rech Epidemiol Picardie, Somme Canc Registry, F-80054 Amiens 1, France
[17] Herault Canc Registry, F-34298 Montpellier 5, France
[18] Univ Liverpool, Mersey Canc Registry, Liverpool L69 3GB, Merseyside, England
关键词
breast cancer; population-based studies; relative survival; predictive factors; relative excess risk of death;
D O I
10.1038/sj.bjc.6602153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990-1992 from cancer registries in Estonia, France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular plus mixed carcinoma, comedocarcinoma, 'special types', medullary carcinoma, not otherwise specified (NOS) carcinoma, other carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61-71) for NOS carcinoma to 95% (95% CI 90-100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27% (95% CI 18-36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age and stage at diagnosis.
引用
收藏
页码:1263 / 1268
页数:6
相关论文
共 50 条
  • [31] Prognostic significance of tumor subtypes in male breast cancer: a population-based study
    Leone, Jose Pablo
    Leone, Julieta
    Osvaldo Zwenger, Ariel
    Iturbe, Julian
    Teodoro Vallejo, Carlos
    Amadeo Leone, Bernardo
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 601 - 609
  • [32] Prognostic significance of tumor subtypes in male breast cancer: a population-based study
    José Pablo Leone
    Julieta Leone
    Ariel Osvaldo Zwenger
    Julián Iturbe
    Carlos Teodoro Vallejo
    Bernardo Amadeo Leone
    Breast Cancer Research and Treatment, 2015, 152 : 601 - 609
  • [33] Radiotherapy in elderly breast cancer patients with hormone therapy: A population-based study
    Medenwald, D.
    Glowka, A.
    Vordermark, D.
    Medenwald, K.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S721 - S722
  • [34] Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study
    Zhang, Di
    Zhai, Jingtong
    Li, Lixi
    Wu, Yun
    Ma, Fei
    Xu, Binghe
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (22)
  • [35] Are single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study
    Li, Y.
    Wu, Y.
    Yang, D.
    Li, H.
    Ren, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
    Yiqun Han
    Yun Wu
    Hangcheng Xu
    Jiayu Wang
    Binghe Xu
    International Journal of Clinical Oncology, 2022, 27 : 707 - 716
  • [37] The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
    Han, Yiqun
    Wu, Yun
    Xu, Hangcheng
    Wang, Jiayu
    Xu, Binghe
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (04) : 707 - 716
  • [38] Human Epidermal Growth Factor Receptor 2 Status and Interval Breast Cancer in a Population-Based Cancer Registry Study
    Musolino, Antonino
    Michiara, Maria
    Conti, Giovanni Maria
    Boggiani, Daniela
    Zatelli, Marella
    Palleschi, Dario
    Bella, Maria Angela
    Sgargi, Paolo
    Di Blasio, Beatrice
    Ardizzoni, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) : 2362 - 2368
  • [39] Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast Cancer
    Sheng Chen
    Can-Ming Chen
    Ke-Da Yu
    Ruo-Ji Zhou
    Zhi-Ming Shao
    Annals of Surgical Oncology, 2012, 19 : 3002 - 3011
  • [40] Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy
    Tacca, Olivier
    Penault-Llorca, Frederique
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Raoelfils, Ines
    Durando, Xavier
    Achard, Jean-Louis
    Gimbergues, Pierre
    Cure, Herve
    Chollet, Phillipe
    ONCOLOGIST, 2007, 12 (06): : 636 - 643